Genetic Variation in Tumor Suppressor miRNAs and Target Genes in Breast Cancer

A supplementary document details a study of genetic variations in tumor suppressor miRNAs and their target genes in 208 breast cancer patients. The research, authored by Yogita Chhichholiya and last updated in March 2026, includes results from sequencing, luciferase assays, and survival analysis. It identifies specific variants in the KRAS 3'UTR that impair miRNA binding and correlate with gene expression and patient outcomes.

Use Cases

• Study the impact of specific genetic variants (rs712, rs9266) on miRNA-target gene interactions based on the described luciferase assay results.
• Analyze the correlation between miRNA expression levels (hsa-let-7c, hsa-miR-181c) and patient survival outcomes based on the Kaplan-Meier analysis mentioned.
• Evaluate KRAS expression as a potential predictive biomarker for chemotherapy response based on the ROC analysis described.

Strengths

• Study includes data from 208 breast cancer patients.
• Functional validation was performed using luciferase assay, RT-PCR, IHC, and Western blotting.
• Analysis utilized multiple bioinformatics tools (RNAfold, TNM plot, Kaplan-Meier Plotter, ROC Plotter).

Limitations

• The primary data file is a 4.3 MB DOCX document; underlying raw or processed data tables are not directly specified.
• Row and column counts for any underlying datasets are unknown, limiting suitability assessment.
• Description metadata is limited; actual data quality requires manual inspection after download.

Provenance

Source

figshare, author Yogita Chhichholiya

Collection Method

Sequencing of miRNA encoding regions and 3'UTRs of target genes in patient samples, followed by functional assays and bioinformatics analysis.

Freshness

Last updated 2026-03-18 07:39:40